Temuterkib
As of the edition of 20 October 2026, Temuterkib is a small molecule: stopped in 2024; acts on MAPK1 and MAPK3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 9, 3 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Lungs and airways; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 |
| Phase 2 | 3 | 1 | 1 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2016 to now |